Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Bonnie Herzog Issues Sell Rating on Clorox

Elaine Mendonca by Elaine Mendonca
March 1, 2024
in Breaking News
0
Global supply chain
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

Goldman Sachs analyst Bonnie Herzog has recently reevaluated Clorox (NYSE: CLX) and issued a Sell rating with a target price of $140 on March 1, 2024. Herzog’s assessment suggests a pessimistic view of the company’s future performance. For more information about Bonnie Herzog’s background, check out her profile on LinkedIn. The Wall Street Journal has also referenced Herzog in an article covering a range of topics, from politics to economics.

CLX Stock Price Update: March 1, 2024 Analysis and Long-Term Outlook

On March 1, 2024, Clorox Co. (CLX) experienced a slight decrease in its stock price. The stock closed at $153.31, which was a decrease of $0.17 or 0.11% from the previous trading day. Additionally, in pre-market trading, the stock dropped a further $0.81.

Despite this recent dip in price, CLX is still trading in the middle of its 52-week range and above its 200-day simple moving average. This indicates that the stock has been relatively stable over the long term and is currently in a strong position compared to its historical performance.

Investors should conduct thorough research and analysis before making any investment decisions based on short-term fluctuations in stock prices. It’s also important to consider the company’s fundamentals, market trends, and long-term growth potential when evaluating the performance of a stock like CLX.

Overall, while CLX may have experienced a slight drop in its stock price on March 1, 2024, the stock’s position in relation to its 52-week range and moving average suggests that it remains a strong and stable investment option for long-term investors.

Clorox Company (CLX) Stock Performance Analysis: Revenue and Profitability Show Strong Growth in Short Term

On March 1, 2024, Clorox Company (CLX) saw some interesting movements in its stock performance based on the financial data provided by CNN Money. Total revenue for the company stood at $7.39 billion for the past year, showing a 3.97% increase compared to the previous year. However, the total revenue for the second quarter was reported at $1.99 billion, reflecting a significant 43.58% increase from the previous quarter. Net income for Clorox Company was reported at $149.00 million for the past year, showing a decrease of 67.75% compared to the previous year. However, the net income for the second quarter was $93.00 million, reflecting a substantial 322.73% increase from the previous quarter. Earnings per share (EPS) for Clorox Company stood at $1.20 for the past year, showing a decrease of 67.82% compared to the previous year. However, the EPS for the second quarter was reported at $0.75, reflecting a significant 322.83% increase from the previous quarter. Overall, the stock performance of Clorox Company on March 1, 2024, seems to have been influenced by the strong growth in revenue and profitability in the short term. Investors may want to keep an eye on how the company continues to perform in the coming quarters to assess its long-term growth prospects.

Tags: CLX
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
DVY stock news

Analysts Bullish on GoodRx Holdings Inc Following Strong Q4 FY23 Results

Title Lexaria Bioscience Receives FDA Approval for Hypertension Clinical Trial with DehydraTECHCBD

Fiances and technology

NetApp Inc Exceeds Expectations with Strong ThirdQuarter Results and Positive Analyst Outlook

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com